
WTTC calls projected decline in international visitors 'a wake-up call' for U.S.
The U.S. is on track to lose $12.5 billion in international visitor spending this year and is projected to be the only country among the 184 analyzed that is forecast to see inbound visitor spending decline in 2025, the World Travel & Tourism Council (WTTC) said today.
The latest Economic Impact Research from the WTTC and Oxford Economics found that international visitor spending to the U.S. is projected to fall to just under $169 billion this year, down from $181 billion in 2024, a 22.5% decline compared to the previous peak.
"The U.S. is welcoming fewer visitors from its neighbors and countries further afield, which is a clear indicator that the global appeal of the U.S. is slipping," the organization said.
• On the Folo podcast: The state of travel today
The downturn, it added, will impact "communities, jobs and businesses from coast to coast."
"This is a wake-up call for the U.S. government," Julia Simpson, the WTTC's CEO, said in a statement. "The world's biggest travel and tourism economy is heading in the wrong direction, not because of a lack of demand but because of a failure to act. While other nations are rolling out the welcome mat, the U.S. government is putting up the 'closed' sign."
The concern echoes that of the U.S. Travel Association, whose CEO, Geoff Freeman, recently said that the $50 billion travel trade surplus the U.S. enjoyed 10 years ago has swung to a $50 billion deficit, a $100 billion reversal that threatens to get worse, and called for a welcoming message to potential travelers.
A long road back?
Simpson added that without urgent action to restore international traveler confidence, it could take several years for the U.S. just to return to prepandemic levels of international visitor spend, not even the peak from 10 years ago.
"This is about growth in the U.S. economy -- it is doable, but it needs leadership from DC," she said.
Simpson did not cite any of the probable reasons for the downturn, such as the tariffs and tariff threats on countries around the world; President Trump's rhetoric about making Canada the 51st U.S. state; and concerns from European governments about the detainment of European tourists at the Canada and Mexico borders.
The WTTC said that U.S. Department of Commerce numbers from March show a "sharp and widespread drop in inbound travel from many of the country's key source markets, such as the U.K. down nearly 15% year over year, Germany down 28%, South Korea down 15% and other key markets such as Spain, Colombia, Ireland, Ecuador and the Dominican Republic all seeing double-digit drops between 24% and 33%.
"As widely expected, the Canadian market is drying up, with early summer bookings down over 20% compared to last year," the report said. "This is more than a dip. It's a wake-up call."
U.S. is 'losing its crown'
The WTTC said that in 2024, nearly 90% of all tourism spending came from domestic travel, with Americans vacationing at home in record numbers. The organization said this heavy reliance on "homegrown tourism is masking a serious vulnerability: The international market is where the real growth lies, and the U.S. is losing its crown." In 2019, the WTTC said, international visitors to the U.S. generated $217.4 billion in revenue and supported almost 18 million jobs.
"Today, that legacy is under threat," the organization said. "WTTC is calling for immediate action to address travel access, rebuild international marketing efforts and restore global traveler confidence in the U.S."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
21 minutes ago
- Associated Press
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas' registration statement for the initial public offering held on or about September 13, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 8, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zenas BioPharma, Inc. ('Zenas' or the 'Company') (NASDAQ: ZBIO) and reminds investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Zenas BioPharma materially overstated the amount of time it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared. When the true details entered the market, the lawsuit claims that investors suffered damages. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Zenas' conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Zenas BioPharma class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit


Associated Press
21 minutes ago
- Associated Press
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action
NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Organon & Co. (NYSE: OGN) between October 31, 2024 and April 30, 2025, both dates inclusive (the 'Class Period'), of the important July 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Organon securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Organon class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 22, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Organon's priorities, particularly, related to capital allocation through quarterly dividends. Notably, defendants concealed the high priority of Organon's debt reduction strategy following Organon's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Organon class action, go to call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]


Fox News
24 minutes ago
- Fox News
National guard deployed by Trump in LA as protesters clash with ICE
All times eastern Maria Bartiromo's Wall Street Maria Bartiromo's Wall Street FOX News Radio Live Channel Coverage